New Orphazyme CEO has great ambitions: Wants to create new Genmab

Christophe Bourdon, who has just taken on the role of CEO at Orphazyme, wants to work on reestablishing the confidence in the company, which suffered greatly following the firm's recent clinical failure.

Photo: Orphazyme/PR

Orphazyme's newly appointed CEO Christophe Bourdon certainly does not lack ambition. Within the next ten years, he sees potential for turning Orphazyme into the new Genmab – but with a focus on rare diseases, according to Danish newspaper Børsen.

Before reaching this point, however, he plans to start remedying the disappointment which the company recently had in a clinical trial for the muscle-wasting disease Inclusion Body Myositis (IBM), which caused the firm's share price to plummet.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs